Aliases & Classifications for Australia Antigen

MalaCards integrated aliases for Australia Antigen:

Name: Australia Antigen 58

Characteristics:

OMIM:

58
Inheritance:
autosomal recessive vs. multifactorial


HPO:

33

External Ids:

OMIM 58 209800
MedGen 43 C0019168

Summaries for Australia Antigen

MalaCards based summary : Australia Antigen is related to hepatitis and viral hepatitis. The drugs Aluminum hydroxide and Neomycin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are global developmental delay and autism

Wikipedia : 77 HBsAg (also known as the Australia antigen) is the surface antigen of the hepatitis B virus (HBV). It... more...

Description from OMIM: 209800

Related Diseases for Australia Antigen

Diseases related to Australia Antigen via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
# Related Disease Score Top Affiliating Genes
1 hepatitis 10.8
2 viral hepatitis 10.5
3 hepatitis b 10.4
4 liver disease 10.4
5 hepatitis a 10.1
6 lepromatous leprosy 10.1
7 hepatocellular carcinoma 10.0
8 arthritis 10.0
9 leukemia 10.0
10 rheumatoid arthritis 9.9
11 acrodermatitis 9.9
12 polyarteritis nodosa 9.9
13 gianotti crosti syndrome 9.9
14 glomerulonephritis 9.9
15 vasculitis 9.9
16 biliary cirrhosis, primary, 1 9.8
17 systemic lupus erythematosus 9.8
18 rheumatic fever-related antigen 9.8
19 autoimmune hepatitis 9.8
20 liver cirrhosis 9.8
21 primary biliary cirrhosis 9.8
22 rheumatic fever 9.8
23 syphilis 9.8
24 rubella 9.8
25 lupus erythematosus 9.8
26 primary biliary cholangitis 9.8
27 pfeiffer syndrome 9.6
28 cirrhosis, familial 9.6
29 kuru 9.6
30 autoimmune lymphoproliferative syndrome, type v 9.6
31 biliary atresia 9.6
32 agammaglobulinemia 9.6
33 pulmonary tuberculosis 9.6
34 collagen disease 9.6
35 hemophilia 9.6
36 encephalopathy 9.6

Graphical network of the top 20 diseases related to Australia Antigen:



Diseases related to Australia Antigen

Symptoms & Phenotypes for Australia Antigen

Human phenotypes related to Australia Antigen:

33
# Description HPO Frequency HPO Source Accession
1 global developmental delay 33 HP:0001263
2 autism 33 HP:0000717

Symptoms via clinical synopsis from OMIM:

58
Neuro:
autism
social, language, and cognitive development impaired

Clinical features from OMIM:

209800

Drugs & Therapeutics for Australia Antigen

Drugs for Australia Antigen (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 21645-51-2
2
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
3
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 198153-51-4 5360545
4
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 142217-69-4 153941
5
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
6
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
7
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147127-20-6 464205
8
Adefovir dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 142340-99-6 60871
9
Ibuprofen Approved Phase 4 15687-27-1 3672
10
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
11
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
12
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
13
Levonorgestrel Approved, Investigational Phase 4,Not Applicable 797-63-7, 17489-40-6 13109
14
Polyestradiol phosphate Approved Phase 4 28014-46-2
15
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
16
Zidovudine Approved Phase 4,Not Applicable 30516-87-1 35370
17
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
18
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
19
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 2 60-18-4 6057
20
Clevudine Investigational Phase 4 163252-36-6
21
Adefovir Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106941-25-7
22 Aluminum phosphate Phase 4
23 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Hepatitis B Antibodies Phase 4
26 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
27 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Interferon-alpha Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Interferon alpha-2 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
32 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 2,Phase 3,Phase 1
35 Antirheumatic Agents Phase 4,Phase 2,Not Applicable
36 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Brewer's Yeast Phase 4,Phase 2,Phase 3
38 Tin Fluorides Phase 4
39 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Protective Agents Phase 4,Phase 3
43 Cariostatic Agents Phase 4
44 Fluorides Phase 4
45
Tin Phase 4 7440-31-5
46 Hepatitis A Antibodies Phase 4,Phase 3
47 Diphtheria Antitoxin Phase 4,Phase 3
48 Antidotes Phase 4,Phase 3
49 Antitoxins Phase 4,Phase 3
50 Tetanus Antitoxin Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 304)
# Name Status NCT ID Phase Drugs
1 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
2 Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg) Completed NCT00240539 Phase 4
3 Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students Completed NCT01861613 Phase 4
4 Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine Completed NCT00524576 Phase 4
5 Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers Completed NCT00240500 Phase 4
6 An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B Completed NCT01787279 Phase 4 Peginterferon alfa-2a [Pegasys]
7 Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth Completed NCT00106964 Phase 4
8 Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV Completed NCT00501124 Phase 4 Clevudine
9 Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder Completed NCT01847430 Phase 4
10 Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine. Completed NCT00774995 Phase 4
11 Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine. Completed NCT00456625 Phase 4
12 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus Completed NCT01627340 Phase 4
13 Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination Completed NCT00684671 Phase 4
14 Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination Completed NCT00984139 Phase 4
15 Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge Completed NCT00411697 Phase 4
16 Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination. Completed NCT00519649 Phase 4
17 Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in China Completed NCT02898922 Phase 4
18 Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B Completed NCT02901951 Phase 4
19 Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection Completed NCT02097004 Phase 4 Entecavir
20 Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV Completed NCT01637844 Phase 4 Telbivudine
21 Immunologic Memory (Supp. of ATN 024) Completed NCT00142753 Phase 4
22 Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B Completed NCT01277601 Phase 4 TDF;Peg-IFN
23 Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB Completed NCT01320943 Phase 4 TDF
24 Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult Completed NCT01037114 Phase 4
25 Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult Completed NCT01000324 Phase 4
26 LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers Completed NCT00240526 Phase 4
27 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
28 A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B Completed NCT00940485 Phase 4 entecavir;entecavir;peginterferon alfa-2a [Pegasys]
29 Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™ Completed NCT00875485 Phase 4
30 A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program Completed NCT02791269 Phase 4 Peginterferon alfa-2a
31 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. Completed NCT01519921 Phase 4 peginterferon alfa-2a [Pegasys]
32 A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B Completed NCT02598063 Phase 4 Adefovir dipivoxil;Lamivudine;Peginterferon alfa-2a
33 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B. Completed NCT00487747 Phase 4 peginterferon alfa-2a [Pegasys]
34 A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection Completed NCT00736190 Phase 4 Tenofovir disoproxil fumarate
35 Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine Completed NCT00657657 Phase 4
36 Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment Completed NCT01235949 Phase 4 Ibuprofen;Paracetamol
37 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB). Completed NCT00435825 Phase 4 peginterferon alfa-2a [Pegasys]
38 A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B Completed NCT00436163 Phase 4 Peginterferon alfa-2a
39 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
40 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B Completed NCT00922207 Phase 4 Adefovir;Entecavir;Placebo;peginterferon alfa-2a [Pegasys]
41 Long-Term Lamivudine Therapy for Chronic Hepatitis B Completed NCT00120354 Phase 4
42 HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP) Completed NCT01808352 Phase 4 FTC/TDF
43 Continuous Use of COCs Completed NCT00570440 Phase 4 Oral contraceptives--ethinyl estradiol, levonorgestrel
44 A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B Completed NCT00927082 Phase 4 peginterferon alfa-2a [Pegasys]
45 Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Completed NCT00371150 Phase 4 Entecavir
46 An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB) Completed NCT01205165 Phase 4 Adefor dipivoxil
47 A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) Completed NCT02604823 Phase 4 Peginterferon alfa-2a
48 Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis Completed NCT00347009 Phase 4 adefovir dipivoxil
49 Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection Completed NCT00127959 Phase 4 tenofovir;emtricitabine;zidovudine;efavirenz
50 Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814 Completed NCT00403585 Phase 4 adefovir dipivoxil 10mg

Search NIH Clinical Center for Australia Antigen

Genetic Tests for Australia Antigen

Anatomical Context for Australia Antigen

MalaCards organs/tissues related to Australia Antigen:

42
Liver, Testes, Kidney, T Cells, Bone, Smooth Muscle, Heart

Publications for Australia Antigen

Articles related to Australia Antigen:

(show top 50) (show all 739)
# Title Authors Year
1
Hepatitis B: 50 years after the discovery of Australia antigen. ( 26280668 )
2016
2
The end of the Australia antigen? An ecological study of the impact of universal newborn hepatitis B vaccination two decades on. ( 23036497 )
2012
3
The Australia antigen and role of the late Philadelphia General Hospital in reducing post-transfusion hepatitis and sequelae. ( 21809361 )
2011
4
Hepatitis B: review of development from the discovery of the "Australia Antigen" to end of the twentieth Century. ( 16190102 )
2004
5
The unexpected outcomes of medical research: serendipity and the Australia antigen. Blumberg BS, Alter HJ, Visnich S. A new antigen in leukemia sera [J Am Med Assoc 1965;191:541-546]. ( 12873809 )
2003
6
Prevalence of Australia antigen (HBsAg) in institutionalised patients with psychosis. ( 8038945 )
1994
7
Observations on Australia antigen in Japanese. Vox Sang 1968:15:374-85. ( 8362521 )
1993
8
AUSTRALIA ANTIGEN (HBsAG) IN INSTITUTIONALISED SCHIZOPHRENICS. ( 21776164 )
1993
9
Seroprevalence of HIV antibodies, Australia antigen and VDRL reactivity in Himachal Pradesh. ( 1819555 )
1991
10
Incidence of australia antigen (HBs Ag) in Himachal Pradesh. ( 2098421 )
1990
11
A study of incidence of Australia antigen and derangements in liver function tests in leprosy. ( 2703743 )
1989
12
Australia antigen (HBsAg) in patients with liver disease and hospital personnel in Shimla, Himachal Pradesh. ( 3454355 )
1987
13
Australia Antigen and Its Sexual Transmission. ( 28150655 )
1986
14
Australia antigen and the prevention of posttransfusion hepatitis. ( 3881877 )
1985
15
Australia antigen testing for various blood products. ( 4055674 )
1985
16
Landmark perspective: The Australia antigen. ( 6374189 )
1984
17
Detection of the relation between the Australia antigen and hepatitis B virus. ( 6380107 )
1984
18
Prevalence of Australia antigen in blood donors of Rajendra Medical College Hospital, Ranchi. ( 6545897 )
1984
19
Incidence of hepatitis B (Australia) antigen among three communities in malarial Western Maharashtra, India. ( 6885085 )
1983
20
Immunological vasculitis-induced neuropathies during chronic hepatitis with Australia antigen positivity. ( 7113780 )
1982
21
[Significance of the presence of Australia antigen in liver diseases seen in a department of internal medicine in Abidjan]. ( 6297069 )
1982
22
Incidence of Australia antigen in leprosy. ( 6783781 )
1981
23
Infectivity in hepatitis B surface antigen (Australia antigen) positive patients. ( 6936049 )
1981
24
Australia antigen-antibody in hepatitis and other chronic liver disorder. ( 7328075 )
1981
25
ABO blood groups in relation to hepatitis-B surface antigen (Australia antigen). ( 7330923 )
1981
26
Prevalence of Australia Antigen (HBs Ag) in Sexually Transmitted Diseases. ( 28211372 )
1981
27
Biochemical genetics and mental retardation: a study of hemoglobins, Australia antigen and the enzymes pseudocholinesterase and glucose-6-phosphate dehydrogenase. ( 7271994 )
1980
28
Australia antigen study in massive blood transfusion. ( 7461768 )
1980
29
[Presence of Australia antigen in blood donors]. ( 7224843 )
1980
30
Australia antigen: the antigen of hepatitis type B. ( 117143 )
1979
31
Community nursing. Australia antigen positive: self-interest says 'keep it quiet.'. ( 260183 )
1979
32
Papular acrodermatitis of childhood. (The Gianotti-Crosti disease). An Australia antigen disease. ( 757836 )
1978
33
Son of Australia antigen? ( 82743 )
1978
34
Australia antigen in diabetics. ( 556103 )
1978
35
Preliminary investigation of bilharzial patients for the presence of Australia antigen using latex agglutination test. ( 648457 )
1978
36
Persistence of Australia antigen in leprosy--a frustrating puzzle in immunology. ( 651319 )
1978
37
The significance of the Australia antigen (HBsAg) persistent healthy carrier "status": a long-term follow-up study of 34 cases. ( 665117 )
1978
38
The genetic hypothesis for the transmission of Australia antigen (HBsAg). ( 717557 )
1978
39
Australia antigen in etiopathogenesis of rheumatic fever. ( 750470 )
1978
40
Periarteritis nodosa with a positive Australia antigen in a two-year-old. ( 17320 )
1977
41
Subtypes of Australia antigen in persistent Australia antigenemia and sporadic hepatitis among patients with lepromatous leprosy and their segregated children with no apparent clinical illness. ( 68939 )
1977
42
Mendelian inheritance or transmissible agent? The lesson Kuru and the Australia antigen. ( 146739 )
1977
43
Australia antigen and the biology of hepatitis B. ( 325649 )
1977
44
Evaluation of passive hemagglutination techniques in detection of Australia antigen (HBsAg). ( 413225 )
1977
45
Hepatic pathologic condition in asymptomatic Australia antigen carriers. A light microscopical study of 26 cases and a review of the literature. ( 579306 )
1977
46
Updating the Australia antigen. Part 1. ( 584402 )
1977
47
Updating the Australia antigen. Diagnosing, treating, and preventing infective hepatitis. ( 584413 )
1977
48
The prevalence of HB-Ag (Australia antigen) in the population of Liberia. ( 594771 )
1977
49
Health status of professional blood donors of Calcutta with special reference to Australia antigen. ( 598916 )
1977
50
Australia antigen (HBsAg) in thallassemia children receiving multiple transfusions. ( 604273 )
1977

Variations for Australia Antigen

Expression for Australia Antigen

Search GEO for disease gene expression data for Australia Antigen.

Pathways for Australia Antigen

GO Terms for Australia Antigen

Sources for Australia Antigen

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....